Income Taxes - Deferred Tax Assets And Liabilities (Details) - USD ($)
$ in Thousands |
Dec. 31, 2018 |
Dec. 31, 2017 |
| Significant components of the Company's deferred tax assets and liabilities |
|
|
| Intangible assets |
$ 1,146
|
$ 1,698
|
| Deferred revenue |
9,304
|
8,083
|
| Interest expense |
5,239
|
|
| Other reserves and accruals |
592
|
850
|
| Tax credit carryforwards |
3,065
|
2,682
|
| Amortization of stock-based compensation |
8,442
|
6,904
|
| Non-Compensatory Warrants |
3,597
|
4,555
|
| Capitalized research & development expenditures |
23,410
|
19,162
|
| Net operating loss carryforwards |
58,364
|
48,078
|
| Total deferred tax asset |
113,159
|
92,012
|
| Valuation allowance |
(100,493)
|
(89,758)
|
| Net deferred tax assets |
12,666
|
2,254
|
| Intangible assets |
(37)
|
(76)
|
| Convertible debt |
(9,217)
|
|
| Property, plant and equipment and right of use assets |
(3,392)
|
(1,969)
|
| Section 382 recognized built in loss |
0
|
(209)
|
| Deferred tax liability |
(12,666)
|
(2,254)
|
| U.S. |
|
|
| Significant components of the Company's deferred tax assets and liabilities |
|
|
| Deferred revenue |
9,304
|
8,083
|
| Interest expense |
5,239
|
|
| Other reserves and accruals |
592
|
850
|
| Tax credit carryforwards |
1,865
|
1,378
|
| Amortization of stock-based compensation |
8,442
|
6,904
|
| Non-Compensatory Warrants |
3,597
|
4,555
|
| Capitalized research & development expenditures |
19,116
|
14,496
|
| Net operating loss carryforwards |
49,058
|
39,437
|
| Total deferred tax asset |
97,213
|
75,703
|
| Valuation allowance |
(84,567)
|
(73,564)
|
| Net deferred tax assets |
12,646
|
2,139
|
| Intangible assets |
(37)
|
(76)
|
| Convertible debt |
(9,217)
|
|
| Property, plant and equipment and right of use assets |
(3,392)
|
(1,854)
|
| Section 382 recognized built in loss |
|
(209)
|
| Deferred tax liability |
(12,646)
|
(2,139)
|
| Foreign |
|
|
| Significant components of the Company's deferred tax assets and liabilities |
|
|
| Intangible assets |
1,146
|
1,698
|
| Tax credit carryforwards |
1,200
|
1,304
|
| Capitalized research & development expenditures |
4,294
|
4,666
|
| Net operating loss carryforwards |
9,306
|
8,641
|
| Total deferred tax asset |
15,946
|
16,309
|
| Valuation allowance |
(15,926)
|
(16,194)
|
| Net deferred tax assets |
20
|
115
|
| Property, plant and equipment and right of use assets |
|
(115)
|
| Deferred tax liability |
$ (20)
|
$ (115)
|